Fan Xiaoyuan, Wang Kaiyuan, Lu Qi, Lu Yutong, Liu Fengxiang, Li Lu, Li Songhao, Ye Hao, Zhao Jian, Cao Liping, Zhang Haotian, He Zhonggui, Sun Jin
Department of Pharmaceutics, Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China.
Multi-Scale Robotics Lab (MSRL), Institute of Robotics & Intelligent Systems (IRIS), ETH Zurich, 8092 Zurich, Switzerland.
Acta Biomater. 2022 Dec;154:412-423. doi: 10.1016/j.actbio.2022.10.031. Epub 2022 Oct 21.
Nanoparticle-anchored platelet systems hold great potential to act as drug carriers in post-surgical cancer treatment due to their intrinsic ability to target the bleeding sites. However, rational design is still needed to further improve its cargo release profiles to meet the cytosolic delivery of therapeutic proteins with intracellular targets. Herein, we developed a tumor microenvironment (TME)-responsive backpack-conjugated platelet system to enhance intracellular protein delivery, thereby significantly inhibiting tumor recurrence after surgery. Specifically, protein nanogels encapsulating GALA and Granzyme B (GrB) are conjugated on the platelet surface via an acid-sensitive benzoic-imine linker through a biorthogonal reaction (GALA-GNGs-P). Taking advantage of wound-tropism of platelets, GALA-GNGs-P could actively accumulate at the surgical trauma and release nanogels in response to acidic TME for promoting deep penetration. Following cellular uptake, the pore-forming peptide GALA helps nanogels escape from lysosome. Subsequently, high glutathione (GSH) concentration in tumor cytoplasm facilitates GrB release from NGs, leading to intense cell apoptosis. GALA-GNGs-P shows remarkable tumor-targeting capability, high cellular uptake, and outstanding lysosomal escaping ability, which can significantly inhibit tumor recurrence in mice models with incomplete tumor resection. Our findings indicate that platelets bioengineered with TME-responsive protein nanogels provide an option to intracellularly deliver therapeutic proteins for the post-surgical treatment of cancer. STATEMENT OF SIGNIFICANCE: Platelet-based drug delivery systems (DDSs) have gained considerable achievements in post-surgical cancer treatment. However, there is no research exploring their potential in realizing the controllable release of cargoes in the acidic tumor microenvironment (TME). Herein, we developed a TME-responsive bioengineered platelet delivery platform (GALA-GNGs-P) for achieving controllable and effective protein intracellular delivery to overcome post-surgical tumor recurrence. Our surface-anchored nanogel-platelet system has the following advantages: (i) improving the loading efficiency of therapeutic proteins, (ii) affecting no physiological function of platelets, (iii) realizing on-demand cargo release in the acidic TME, and (iv) helping proteins escape from endosomal entrapment. Our findings further explored the prospect of cellular backpack system and realized the controllable release of cargoes in the acidic TME.
纳米颗粒锚定的血小板系统因其内在的靶向出血部位的能力,在术后癌症治疗中作为药物载体具有巨大潜力。然而,仍需要合理设计以进一步改善其药物释放特性,以满足具有细胞内靶点的治疗性蛋白质的胞质递送。在此,我们开发了一种肿瘤微环境(TME)响应性背包共轭血小板系统,以增强细胞内蛋白质递送,从而显著抑制术后肿瘤复发。具体而言,包裹GALA和颗粒酶B(GrB)的蛋白质纳米凝胶通过生物正交反应,经由酸敏性苯甲亚胺连接子共轭在血小板表面(GALA-GNGs-P)。利用血小板的伤口趋向性,GALA-GNGs-P可在手术创伤处主动聚集,并响应酸性TME释放纳米凝胶以促进深度渗透。细胞摄取后,成孔肽GALA帮助纳米凝胶从溶酶体逃逸。随后,肿瘤细胞质中高浓度的谷胱甘肽(GSH)促进GrB从纳米凝胶中释放,导致强烈的细胞凋亡。GALA-GNGs-P表现出显著的肿瘤靶向能力、高细胞摄取率和出色的溶酶体逃逸能力,可在肿瘤切除不完全的小鼠模型中显著抑制肿瘤复发。我们的研究结果表明,用TME响应性蛋白质纳米凝胶进行生物工程改造的血小板为癌症术后治疗的细胞内递送治疗性蛋白质提供了一种选择。重要性声明:基于血小板的药物递送系统(DDSs)在术后癌症治疗中已取得了相当大的成就。然而,尚无研究探索其在酸性肿瘤微环境(TME)中实现可控药物释放的潜力。在此,我们开发了一种TME响应性生物工程血小板递送平台(GALA-GNGs-P),以实现可控且有效的蛋白质细胞内递送,克服术后肿瘤复发。我们的表面锚定纳米凝胶-血小板系统具有以下优点:(i)提高治疗性蛋白质的负载效率,(ii)不影响血小板的生理功能,(iii)在酸性TME中实现按需药物释放,以及(iv)帮助蛋白质从内体包封中逃逸。我们的研究结果进一步探索了细胞背包系统的前景,并实现了在酸性TME中的可控药物释放。